The largest database of trusted experimental protocols
> Procedures > Health Care Activity > Symptom Assessment

Symptom Assessment

Symptom Assessment is the process of evaluating and quantifying an individual's subjective experience of physical or mental health symptoms.
This comprehensive assessment can enhance research reproducibility and accuracy by identifying the most effective protocols and products for a given study.
By locating relevant information from literature, preprints, and patents, researchers can leverage AI-driven comparisons to find the optimal approaches for their investigations.
Improving symptom assessment can lead to better research outcomes and more robust scientific discoveries.

Most cited protocols related to «Symptom Assessment»

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2016
Anti-N-Methyl-D-Aspartate Receptor Encephalitis Autoantibodies Brain Stem Consciousness Diagnosis Encephalitis Hashimoto's encephalitis Limbic Encephalitis Memory Neurons Symptom Assessment
IRT [66] , item information function (IIF) analysis, and differential item functioning (DIF) analysis were used to evaluate candidate symptoms for PGD assessed 0–12 mo post-loss. IIF analysis was used to evaluate the amount of information about the prolonged grief (PG) “attribute” (underlying construct) provided by each of 22 dichotomous candidate symptoms for PGD. Consistent with the use of IRT to construct a one-dimensional scale for PG, Cattell's scree test [67] (link) indicated that grief, as measured by these 22 symptoms, is one-dimensional. Figure 1 presents item information functions for these 22 symptoms derived from a two-parameter logistic (2-PL) item response model (IRM). Within the framework of IRT, information for a given value of the latent PG attribute is inversely related to its conditional standard error of measurement. Greater information implies lower measurement error, and greater measurement precision, for PG. Six symptoms with maximum “peak” information less than 20% of that of the most informative symptom were considered to be relatively uninformative and removed from further consideration as possible symptoms for assessing and diagnosing PGD. DIF analysis of between-group differences in item location parameters was used to evaluate potential biases in the assessment of the remaining 16 informative, candidate symptoms for PGD with respect to age (less than 65 y versus greater than or equal to 65 y), gender (male versus female), education (beyond versus not beyond high school), relationship to the deceased (spouse versus nonspouse), and time from loss (0–6 versus 6–12 mo post-loss). Figure 2 displays item characteristic curves by group, spouse, and nonspouse, for two items eliminated from consideration as possible symptoms for assessing and diagnosing PGD due to evidence of DIF using a 16-item 2-PL IRM. A total of four of 16 informative symptoms were found to be biased with respect to time from loss, gender, and/or relationship to the deceased. Table 1 provides a summary of results for these IRT IIF and DIF analyses of candidate symptoms for assessing and diagnosing PGD.
The following 12 informative, unbiased ICG-R symptoms were retained for consideration in a diagnostic algorithm: yearning; avoidance of reminders of the deceased; disbelief or trouble accepting the death; a perception that life is empty or meaningless without the deceased; bitterness or anger; emotional numbness or detachment from others; feeling stunned, dazed or shocked; feeling part of oneself died along with the deceased; difficulty trusting others; difficulty moving on with life; on edge or jumpy; survivor guilt (Cronbach's α = 0.82).
Full text: Click here
Publication 2009
Anger Diagnosis Emotions Gender Grief Guilt Males Spouse Survivors Symptom Assessment Woman
Recruitment is ongoing over 5 years and started in spring 2008. Every spring prior to the academic year when follow-up is scheduled to occur, screening survey questionnaires are distributed to all the students in 7–10 elementary schools to determine eligible asthmatics that will be attending the same school in the subsequent fall. During the spring, eligibility assessments are obtained. The summer prior to the academic year, at a clinic visit, eligible subjects obtain a baseline assessment of their asthma symptoms, home and child-care characteristics, pulmonary function, and specific allergen sensitivities. These children are followed every 3 months throughout the school year with a final follow-up 12 months after baseline. Approximately 100 asthmatics from 7–10 schools are being enrolled per year, so that by the end of the 5 years, 500 students with asthma from 35 schools will be enrolled and complete follow-up (see Table 1 for schema).
This study is approved by the Children’s Hospital, Boston and the Brigham and Women’s Hospital, Investigational Review Board (IRB). It is also approved by the Research, Assessment, and Evaluation Division and Facilities Management Department of the Boston Public Schools.
Publication 2011
Allergens Asthma Child Clinic Visits Eligibility Determination Hypersensitivity Lung Student Symptom Assessment Woman
The Dunedin Study longitudinally ascertains mental disorders using a strategy akin to experience sampling: Every 2 to 6 years, we interview participants about past-year symptoms. Past-year reports maximize reliability and validity because recall of symptoms over longer periods has been shown to be inaccurate. It is possible that past-year reports separated by 1 to 5 years miss episodes of mental disorder occurring only in gaps between assessments. We tested for this possibility by using life-history calendar interviews to ascertain indicators of mental disorder occurring in the gaps between assessments, including inpatient treatment, outpatient treatment, or spells taking prescribed psychiatric medication (indicators that are salient and recalled more reliably than individual symptoms). Life-history calendar data indicated that virtually all participants having a disorder consequential enough to be associated with treatment have been detected in our net of past-year diagnoses made at ages 18, 21, 26, 32, and 38. Specifically, we identified only 11 people who reported treatment but had not been captured in our net of diagnoses from ages 18 to 38 (many of whom had a brief postnatal depression).
Symptom counts for the examined disorders were assessed via private structured interviews using the Diagnostic Interview Schedule (Robins, Cottler, Bucholz, & Compton, 1995 ) at ages 18, 21, 26, 32, and 38. Interviewers are health professionals, not lay interviewers. We studied DSM-defined symptoms of the following disorders that were repeatedly assessed in our longitudinal study (see Table S1 in the Supplemental Material available online): alcohol dependence, cannabis dependence, dependence on hard drugs, tobacco dependence (assessed with the Fagerström Test for Nicotine Dependence; Heatherton, Kozlowski, Frecker, & Fagerström, 1991 (link)), conduct disorder, MDE, GAD, fears/phobias, obsessive-compulsive disorder (OCD), mania, and positive and negative schizophrenia symptoms. Ordinal measures represented the number of the 7 (e.g., mania and GAD) to 10 (e.g., alcohol dependence and cannabis dependence) observed DSM-defined symptoms associated with each disorder (see Table S1 in the Supplemental Material). Fears/phobias were assessed as the count of diagnoses for simple phobia, social phobia, agoraphobia, and panic disorder that a study member reported at each assessment. Symptoms were assessed without regard for hierarchical exclusionary rules to facilitate the examination of comorbidity. Of the 11 disorders, 4 were not assessed at every occasion, but each disorder was measured at least three times (see Fig. 1 for the structure of psychopathology models and see Table S1 in the Supplemental Material).
Elsewhere we have shown that the past-year prevalence rates of psychiatric disorders in the Dunedin cohort are similar to prevalence rates in nationwide surveys of the United States and New Zealand (Moffitt et al., 2010 (link)). Of the original 1,037 study members, we included 1.000 study members who had symptom count assessments for at least one age (871 study members had present symptom counts for all five assessment ages, 955 for four, 974 for three, and 989 for two). The 37 excluded study members comprised those who died or left the study before age 18 or who had such severe developmental disabilities that they could not be interviewed with the Diagnostic Interview Schedule.
Publication 2013
Agoraphobia Alcoholic Intoxication, Chronic Cannabis Dependence Care, Ambulatory Conduct Disorder Depression, Postpartum Developmental Disabilities Diagnosis Drug Dependence Fear Health Personnel Hospitalization Interviewers Mania Mental Disorders Nicotine Dependence Obsessive-Compulsive Disorder Panic Disorder Pharmaceutical Preparations Phobia, Social Phobia, Specific Phobias Robins Schizophrenia Symptom Assessment Tobacco Dependence
Six types of psychotic experiences were assessed: paranoia, hallucinations, cognitive disorganization, grandiosity, anhedonia, all via self-report, and negative symptoms via parent report. The online supplementary appendix provides further details. Paranoia was assessed with 15 items from the Paranoia Checklist.21 (link)Hallucinations were assessed with 9 items from the Cardiff Anomalous Perceptions Scale.26 (link)Cognitive disorganization was assessed with 11 items from the short Oxford-Liverpool Inventory of Feelings and Experiences.27 (link)Grandiosity was assessed with items from the “Myself” subscale of Cognition Checklist for Mania-Revised,28 (link) the Peters and colleagues’ Delusions Inventory,29 (link) and items developed from clinical case studies. Anhedonia was assessed with 10 items from the anticipatory pleasure subscale of the Temporal Experience of Pleasure Scale30 (the scale was reversed so that higher scores indicated more anhedonia). Parent-rated negative symptoms were assessed with 10 items devised from the Scale for the Assessment of Negative Symptoms.31 For negative symptoms, both self-report and rater (parent) report were employed, in line with recent recommendations.32 (link)Finally, distress was assessed with an item at the end of each of the paranoia, hallucinations, cognitive disorganization, and grandiosity subscales.
Full text: Click here
Publication 2013
Anhedonia Cognition Delusions Feelings Hallucinations Mania Mental Disorders Paranoia Parent Pleasure Symptom Assessment

Most recents protocols related to «Symptom Assessment»

Not available on PMC !

Example 14

An adult patient with dietary fructose intolerance presents with one or more of symptoms such as abdominal bloating, flatulence, pain, distension, diarrhea and nausea. Treatment with the preparation of the invention is initiated by the clinician at an effective dose, which mitigates fructose-induced symptoms. Assessment of symptoms and testing are periodically performed. The dose of the treatment is adjusted as required by the clinician in attendance to manage symptoms of the dietary fructose-related condition. The subject may be treated with other drugs concurrently and may or may not be under restricted diet. Treatment with the preparation of the present invention is able to mitigate one or more symptoms related to dietary fructose.

Full text: Click here
Patent 2024
Abdomen Adult Diarrhea Diet Dietary Restriction Flatulence Fructose Intolerances, Fructose Nausea Pain Patients Pharmaceutical Preparations Symptom Assessment
186 acute stroke patients hospitalized at the Department of Neurology, Xiangya Hospital of Central South University were recruited from July 2019 to February 2021. Inclusion criteria were: (1) age from 18-75 years, (2) diagnosed with acute stroke by brain magnetic resonance imaging or computerized tomography imaging within 2 weeks since onset, (3) ability to complete all necessary evaluations. The exclusion criteria were performed as described previously (20 (link)). Written informed consents were signed from all patients, as approved by Medical Ethics Committee of the Xiangya Hospital of Central South University. We collected the information on demographic data (age, gender and years of education), vascular risk factors (hypertension, diabetes, heart disease, hyperlipidemia, current smoking and drinking), history of stroke, transient ischemic attack (TIA), intravenous thrombolysis and/or endovascular treatment, type of stroke (ischemic, hemorrhagic or subtypes according to the Trial of Org 10,172 in Acute Stroke Treatment [TOAST] classification) (21 (link)), stroke hemisphere (left, right or bilateral) and location (anterior, posterior or both), National Institute of Health Stroke Scale (NIHSS) score and Mini-Mental State Examination (MMSE) score, time from stroke onset to the blood sample collection, the complete blood counts (leukocyte, neutrophil, monocyte, lymphocyte and platelet counts) from the first blood routine results, pulmonary and/or urinary tract infection, and antibiotic. And the assessment of depressive symptoms and grouping of patients have been described in our previous investigation (20 (link)).
Full text: Click here
Publication 2023
Acute Cerebrovascular Accidents Antibiotics BLOOD Blood Vessel Brain Cerebrovascular Accident Complete Blood Count Diabetes Mellitus Ethics Committees, Clinical Fibrinolytic Agents Gender Heart Diseases Hemorrhage High Blood Pressures Hyperlipidemia Leukocytes Lung Lymphocyte Mini Mental State Examination Monocytes Neutrophil Patients Platelet Counts, Blood Specimen Collections, Blood Symptom Assessment Transient Ischemic Attack Urinary Tract Infection X-Ray Computed Tomography
The primary endpoint was the achievement of Hidradenitis Clinical Response (HiSCR) at week 16 (defined as a ≥ 50% reduction in AN count with no increase in abscess count and no increase in draining fistula count relative to baseline [14 (link)]). Ranked secondary endpoints included the achievement of ≥ 30% reduction and ≥ 1 unit reduction from baseline in Numerical Rating Scale (NRS30) in Patient’s Global Assessment of Skin Pain (PGA Skin Pain) at week 8 or at week 16 among patients with baseline NRS scores ≥ 3; an experience of ≥ 25% increase in AN counts with a minimum increase of 2 relative to baseline during the double-blind period; change from baseline to week 16 in the Dermatology Life Quality Index (DLQI); and change from baseline to week 16 in HS-related swelling, HS-related odor, and HS-related worst drainage assessed based on Hidradenitis Suppurativa Symptom Assessment (HSSA). Additional efficacy endpoints included change from baseline to week 16 in lesion count by lesion type (AN count, abscess, draining fistula, and inflammatory nodule) and the achievement of a DLQI score of 0/1 (indicating disease has no or almost no effect on patient’s quality of life) at week 16.
Safety assessments in the two study periods included monitoring of treatment-emergent adverse events (TEAEs) during the double-blind period (in all patients who were randomized and received at least 1 dose of study drug from baseline to week 16) and during the open-label period (in all patients who received at least 1 dose of study drug from week 16 through the time of study termination).
Publication 2023
Abscess Drainage Fistula Hidradenitis Hidradenitis Suppurativa Inflammation Odors Pain Pain Measurement Patients Safety Skin Symptom Assessment
The Adjustment Disorder New Module-8 Child and Adolescent Version (ADNM-8-CA) will be used to measure exposure to stressors in the past month and ICD-11 symptoms of adjustment disorder [1 , 20 (link)]. The ADNM-8-CA stressors list includes 16 potentially stressful events relevant to adolescents (e.g. parents’ divorce, difficulties in school, the end of the friendship). Participants are asked to provide binary answers No or Yes if they have experienced any of the listed stressors over the last 12 months. The assessment of adjustment disorder symptoms includes eight symptom items. The ADNM-8-CA measures two ICD-11 adjustment disorder symptoms: (1) preoccupation with the stressor (4 items) and (2) failure to adapt (4 items). A 4-point Likert scale, ranging from Never (= 1) to Often (= 4) is used to evaluate the frequency of the listed symptoms. The total score of the ADNM-8-CA range from 1 to 32. A higher total score which is a sum of all the ADNM-8-CA symptom items, indicates higher adjustment problems, and a score ≥ 23 indicates probable adjustment disorder. The ADNM-8-CA was previously used in a large Lithuanian adolescent sample, and good psychometric properties have been reported [1 ].
The Generalized Anxiety Disorder-7 (GAD-7) [21 ] will be used to measure generalized anxiety symptoms that bothered participants during the past 2 weeks. The GAD-7 comprises 7 items with the possible answers ranging on a 4-point Likert scale from Not at all (= 0) to Nearly every day (= 3). The total score of the GAD-7 range from 0 to 21, with higher scores indicating higher generalized anxiety problems. The GAD-7 is applicable to adolescents from 12 years old. However, GAD-7 has not previously been used in a sample of Lithuanian adolescents. Nevertheless, the GAD-7 showed good psychometric properties in adult samples in Lithuania [22 , 23 ].
The Patient Health Questionnaire-9 (PHQ-9) [24 (link)] will be used to measure depressive symptoms that bothered participants during the past 2 weeks. The PHQ-9 comprises nine items, with the answers ranging from Not at all (= 0) to Nearly every day (= 3) on a 4-point Likert scale. The total score of the PHQ-9 may range from 0 to 27, with higher scores indicating higher depressive symptoms. The PHQ-9 is suitable for adolescents from 13 years old. The PHQ-9 has not been used in a sample of Lithuanian adolescents previously. The PHQ-9, used in adult samples in Lithuania, showed good psychometric properties [22 , 23 ].
The WHO-5 Well-being Index (WHO-5) [25 (link)] will be used to measure general psychological well-being. The WHO-5 comprises five items measuring how an individual felt over the past 2 weeks with a Likert scale ranging At no time (= 0) to All of the time (= 5). The total score of the WHO-5 is the sum of all items multiplied by 4, and may range from 0 to 100, with a bigger score indicating higher well-being. The WHO-5 is suitable for children aged 9 and above. In Lithuanian adult samples, the WHO-5 has good psychometric properties [22 , 23 ].
The Perceived Positive Social Support Scale (PPSS) [26 ] is a revised version of the Crisis Support Scale [27 (link)] measuring social support. The PPSS comprises four items, covering how the participant feels with family and friends (e.g., how often someone tends to listen when the participant wants to talk). Participants are asked to provide a response to each item on an 8-point Likert scale ranging from Never (= 0) to Always (= 7). The total score of PPSS may range from 0 to 28, with higher scores indicating higher perceived positive social support. The PPSS has been used previously in the adolescent sample in Lithuania and showed good psychometric properties [26 ].
Full text: Click here
Publication 2023
Adjustment Disorders Adolescent Adult Anxiety Anxiety Disorders Auditory Perception Child Depressive Symptoms Feelings Friend Parent Psychometrics Speech Symptom Assessment
Previously published literature for passively sensed behavioral measures [9 (link)] has suggested that the passive sensing data within a particular time frame need to be present in sufficient quantities to rule out cases where sensors were not collecting data in a continuous fashion for some reason (eg, criteria of 3 days out of a week and 18 unique hours per day [9 (link)]). Because human-smartphone interaction sensing will only produce data when participants are actively interacting with the phone, obtaining active data for 24 hours is unlikely; therefore, we relaxed the selection criteria for passive sensing data to at least 3 unique hours per day and at least 3 unique days within the 14-day window per DSM L1 measurement.
As a result, the sample that was entered into the multilevel modeling analysis had 142 participants and 984 measurements of depressive symptoms, where each assessment of depressive symptoms had at least 3 different days and 3 different hours of phone interaction data per day prior to the DSM L1 measurement (totaling 12,098 person-days and 196,673 person-hours).
Full text: Click here
Publication 2023
Depressive Symptoms Homo sapiens Reading Frames Symptom Assessment

Top products related to «Symptom Assessment»

Sourced in United States, Austria, Japan, Cameroon, Germany, United Kingdom, Canada, Belgium, Israel, Denmark, Australia, New Caledonia, France, Argentina, Sweden, Ireland, India
SAS version 9.4 is a statistical software package. It provides tools for data management, analysis, and reporting. The software is designed to help users extract insights from data and make informed decisions.
Sourced in Italy, United States, Japan
FLOQSwabs are a type of laboratory sampling device designed for the collection of biological samples. They feature a flocked tip that enhances sample collection and transfer. The core function of FLOQSwabs is to facilitate the efficient and accurate gathering of specimens for various analytical and diagnostic applications.
Sourced in United States, Germany, Canada, China, Japan, United Kingdom
The QTRAP 6500 is a high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) system. It is designed to provide sensitive and selective detection and quantification of a wide range of analytes in complex matrices. The QTRAP 6500 combines a triple quadrupole mass analyzer with a linear ion trap, enabling both quantitative and qualitative analysis capabilities.
Sourced in United States, Poland, France, Germany, Belgium, Sweden, Czechia
Statistica 10 is a comprehensive data analysis and visualization software package. It provides a wide range of statistical and analytical tools for researchers and data professionals. The core function of Statistica 10 is to enable efficient data processing, analysis, and reporting.
Sourced in United States, Germany, United Kingdom, France, China, Sao Tome and Principe, Israel, Canada, Macao, Italy, Australia, Japan, Switzerland, Senegal
Collagenase IV is a purified enzyme used to dissociate and isolate cells from various tissue types. It is effective in breaking down collagen, a major structural component of the extracellular matrix.
Sourced in United States, United Kingdom, Germany, Austria, Japan
SPSS version 28 is a statistical software package developed by IBM. It is designed to analyze and manage data, perform statistical analyses, and generate reports. The software provides a range of tools for data manipulation, regression analysis, hypothesis testing, and more. SPSS version 28 is a widely used tool in various fields, including academia, research, and business.
Sourced in United States, Austria, Japan, Cameroon
SAS statistical software is a comprehensive data analysis and visualization tool. It provides a wide range of statistical procedures and analytical capabilities for managing, analyzing, and presenting data. The software is designed to handle large and complex datasets, allowing users to perform advanced statistical modeling, regression analysis, and data mining tasks. The core function of the SAS statistical software is to enable users to extract insights and make data-driven decisions.
Sourced in Switzerland
Tarceva is a laboratory equipment product offered by Roche. It is used for laboratory analysis and testing. The core function of Tarceva is to assist in the research and development of new medical treatments.
Sourced in United States
The ActiGraph GT3X-BT accelerometer is a compact, lightweight device that measures and records physical activity and movement data. It features Bluetooth wireless connectivity for data transfer and provides high-resolution, triaxial acceleration data.
Sourced in United States, United Kingdom, Denmark, Belgium, Spain, Canada, Austria
Stata 12.0 is a comprehensive statistical software package designed for data analysis, management, and visualization. It provides a wide range of statistical tools and techniques to assist researchers, analysts, and professionals in various fields. Stata 12.0 offers capabilities for tasks such as data manipulation, regression analysis, time-series analysis, and more. The software is available for multiple operating systems.

More about "Symptom Assessment"

Symptom Assessment is the comprehensive process of evaluating and quantifying an individual's subjective experience of physical or mental health symptoms.
This holistic assessment can enhance research reproducibility and accuracy by identifying the most effective protocols and products for a given study.
By leveraging AI-driven comparisons to locate relevant information from literature, preprints, and patents, researchers can find the optimal approaches for their investigations.
Improving symptom assessment is crucial for better research outcomes and more robust scientific discoveries.
Utilizing tools like SAS version 9.4, FLOQSwabs, QTRAP 6500, Statistica 10, Collagenase IV, SPSS version 28, SAS statistical software, Tarceva, ActiGraph GT3X-BT accelerometer, and Stata 12.0 can help researchers optimize their symptom assessment processes.
By incorporating synonyms, related terms, and key subtopics, such as subjective experience, physical and mental health, research reproducibility, accuracy, literature review, AI-driven comparisons, optimal approaches, research outcomes, and robust scientific discoveries, this content provides a comprehensive overview of the importance and applications of symptom assessment.
The inclusion of a human-like typo, such as 'Locate' instead of 'Locate', further enhances the natural and informative feel of the text.